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Introduction
Dissemination  of  soft  tissue  sarcoma  (STS)  is  in
almost all patients restricted to the lungs. For that
reason, and due to lack of other effective treatment
modalities, a surgical approach of these metastases
became more and more popular since the ￿ rst report
of Weinlecher in 1882.1 After that report, several case
reports and unselected small series were published
with inconsistent results.
In the last decades several reports have shown a
prolonged survival for patients after surgery for lung
metastases from STS. In recent series a post-thora-
cotomy  5-year  survival  of  30%  or  more  has  been
found.2–11 This ￿ nding is in contrast with the results
from chemotherapy trials with a response rate of 25%
or less for a limited period.The question, however, is
whether the group of patients with metastasectomy
and those with chemotherapy alone are comparable.
The patients studied with metastasectomy could be a
positive selection with presumed favorable prognos-
tic factors. In fact, the response data for chemother-
apy as single treatment for lung metastases and other
visceral organs alone are still the subject of EORTC
studies and not published yet.(M.van Glabbeke,per-
sonal  communication) The  natural  course of  STS
metastases, if no treatment is given, is not known.12
Nevertheless,the general accepted opinion is in con-
trast to the conclusion of Frost12 that metastases from
STS con￿ rmed in lung are best treated by surgery. In
the case of concomitant local recurrence, this recur-
rence  should  be  treated  ￿ rst  in  a  radical  way.
Subsequently, the  patient  will  bene￿ t  from  surgery
preferably with low morbidity and a short hospital stay.
One of the old reasons for discussions among tho-
racic and oncological surgeons is the type of surgical
access. For bilateral metastases there is no doubt: a
bilateral exploration,sometimes staged,is mandatory.
For unilateral metastases on CT scan, a trend to
bilateral approach can be seen,because the number of
patients with unsuspected bilateral disease is substan-
tial. Moreover, the morbidity with sternotomy is less
than with thoracotomy.13The accuracy of the CT scan
in predicting the number of metastases was reported to
be 50–60%.14, 15 But with the new generation of CT
scanners this ￿ gure will increase and the chance of
￿ nding  unexpected  contralateral  metastases  will
decrease dramatically.16 In close collaboration with the
radiologist, all metastases should be studied and the
surgeon should decide if radical resection is feasible.
The main goal of this review is to attempt to order
the data from the literature and to give guidelines for
selection of patients for surgical treatment of lung
metastases.
Prognostic factors
Almost all series report an analysis of factors in￿ u-
encing  the  prognosis  after  metastectomy. These
factors are age, gender, histology, grade, disease-free
interval,number of metastases,and radical resection.
The  problem is  that  there is  no agreement and a
de￿ nitive conclusion cannot be made.
The best way to combine results of related studies
is to perform a meta-analysis of all raw data from
these  studies. However, this  requires  considerable
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as  hazard  rates  or  expected  number  of  deaths  in
various subgroups.17
Because these summary data are lacking in almost
all  studies  dealing  with  prognostic  factors  after
surgery of lung metastases  from STS we are con-
demned to the rather crude method of combination
of p values.18
Table 1 shows 10  publications with information
about the p values of the tests for the in￿ uence of
disease-free interval  and number of  metastases  on
overall survival. It is concluded that the length of the
disease-free interval is very important (p = 0.0002);
But it is not clear which cut-off point must be taken.
An interval of at least 7 months or less is a bad prog-
nostic factor.The number of metastases seems not to
be an important factor (p = 0.20).
Repeated pulmonary metastasectomy
It is unclear how many patients develop recurrent pul-
monary metastases after pulmonary metastasectomy.
In fact,only those patients with bilateral thoracotomy
can be considered for calculation of the real recur-
rence rate. In unilateral exploration, occult contralat-
eral  metastases  can  be  easily  missed  as  we  have
shown.14 About 40% of the patients will relapse after
sternotomy, with  a  median  relapse  time  of  about 
2 year.13,15
The general opinion is that there is no strict con-
traindication for subsequent pulmonary exploration,
either by thoracotomy or sternotomy, although the
latter will be more dif￿ cult for technical reasons. Up
to  a  number  of  seven  repeated  thoracotomies  for
metastectomy  have  been  reported  with  long-term
survivors. The only restriction is a very short lung
relapse time: reoperation within 6 months seems to
be  useless because  these  patients  will  have  a  bad 
prognosis anyhow.19, 20
Like the recent report of Kandioler et al., one has
to keep in mind that the data are from series which
include  all  types  of  malignancies.21 However, the
conclusions drawn from these studies probably are
applicable for STS patients as well.
Video-assisted thoracoscopy
In  some  centres, pulmonary  metastasectomy  is
performed by video-assisted thoracoscopy (VATS).22
Although this technique has some advantages to the
classical thoracotomy,there is an important reason to
question this kind of treatment. Open lung surgery
not only offers a good view, but also gives the possi-
bility to palpate the lungs, which is complementary
to the preoperative CT staging  of the lung metas-
tases. VATS resection should be limited to patients
selected by high-resolution CT with only peripheral
lung metastases.23Tumor implants in the trocart sites
have been reported.24 VATS in combination with a
6–8-cm thoracotomy  may be an alternative  proce-
dure, because this allows palpation. Also, preopera-
tive CT-guided localization of the metastases may be
considered to allow easier resection.25
Future
There is a de￿ nitive indication for metastasectomy of
lung  recurrences  of  STS  if  other  signs  of  tumor
activity are lacking.The only restriction to be made
is that the planned surgery must be radical with cura-
tive intent. The general 5-year survival is 25–35%.
Surgery alone cannot improve these data; however,
bilateral exploration, even in unilateral disease, prob-
ably can decrease the number of lung recurrences.
But with the  greatly  improved CT devices (3-mm
slices), this conclusion may be criticized.
Reviewing the literature one can see that a lot of
patients have had chemotherapy in the course of their
metastastic  disease; however, never in a consistent
way as part of treatment protocol for lung metastases
in combination with surgery.26
For  this  reason, some  years  ago  the  EORTC 
Soft  Tissue  and  Bone  Sarcoma  Group  started  a
prospective trial randomizing between preoperative
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Table 1. Analysis of 10 related studies on prognostic factors by combining p values
Author/year Number  Interval P Number  P
of patients of methods
Creagan 1979 112 1 vs >1 year <0.01 1 vs > 1 NS
Takita 1981 234 £7 vs >7 months 0.01 1 vs > 1 <0.01
Jablons 1989 55 £1 vs >1 year 0.03 <5 vs ‡ 5 0.68
Casson 1992 58 £1 vs >1 year 0.90 £ 2 vs >2 0.02
Verazin 1992 78 Continuous 0.02 £5 vs >5 0.96
Ueda 1993 23 <6 vs ‡ 6 months 0.90 £5 vs >5 NS
Saltzman 1993 49 £1 vs 1–£2 vs 0.95* £3 vs >3 0.85
>2 years
Robinson 1994 44 £1 vs >1 year NS £2 vs >2 0.49
Choong 1995 214 £1.5 vs >1.5 year 0.006 1 vs ‡1 0.009
Van Geel 1996 255 £2.5 vs >2.5 year 0.003 £3 vs >4 0.21
This analysis 0.0002 0.02
NS, not signi￿ cant.
*In text mentioned as signi￿ cant.chemotherapy  followed  by  metastasectomy  and
metastasectomy  alone  (EORTC-STBSG  62933).
Because  the  accrual  proved  to  be  very  dif￿ cult,
further  international  collaboration  was  needed  for
success.At a certain moment,the study was running,
as  well  as  in  the  EORTC, in  the  Scandinavian
Sarcoma Group (SSG), in the South West Oncology
Group  (SWOG)  and  in  the  Eastern  Cooperative
Oncology Group (ECOG). Despite these efforts, the
study was closed because it was clear that many years
were  needed  for  acceptable  patient  accrual.
Therefore, we will never know if the combination of
metastasectomy  and  chemotherapy  is  better  than
metastasectomy alone in STS patients.Also,a unique
chance to  prospectively register patients  with  lung
surgery for STS metastases has been missed.
Final conclusion
The ￿ nding of lung metastases means a dramatically
decreased  life  expectancy  for  patients  with  STS.
Chemotherapy  does  not  offer  cure  and, for  that
reason, surgery is widely accepted as ￿ rst line treat-
ment  in  selected  patients. The  most  important 
selection  criterion  is  the  prediction  of  a  radical
removal  of  all  visible  nodules  Other  prognostic
factors are less important or at least debatable, and
grade  has  been  only  studied  in  one  series  with  a
strong signi￿ cance.11 Using the second best method
of meta-analysis,it is signi￿ cantly shown that patients
with an interval of less than 7 months between diag-
nosis of STS and lung surgery do not bene￿ t. All
other parameters, such as age, number of metastases,
etc., do not have any in￿ uence on prognosis. In fact,
the same policy can be followed for recurrent lung
metastases  (Fig. 1). There is  no proof that  (neo-)
adjuvant  chemo-therapy  will  increase  survival  in
comparison to metastesectomy alone, and is there-
fore not indicated.
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